Evidence map›Paper›PMID 32711168›Full record

ArticlePsychiatry research2020

The predictive validity of the progress assessment, a clinician administered instrument for use in measurement-based care for substance use disorders.

Deborah H A Van Horn, Jessica Goodman, Kevin G Lynch, Marcel O Bonn-Miller, Tyrone Thomas, A C Del Re, Kimberly Babson, James R McKay

Abstract read
In one paragraph

Article in Psychiatry research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deborah H A Van HornDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market St, Philadelphia, PA 19104 USA. Electronic address: dvh@vanhornconsulting.com.
Jessica GoodmanDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market St, Philadelphia, PA 19104 USA; Center of Excellence in Substance Abuse Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
Kevin G LynchDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market St, Philadelphia, PA 19104 USA.
Marcel O Bonn-MillerCenter of Excellence in Substance Abuse Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104 USA; National Center for PTSD-Dissemination & Training Division, VA Palo Alto Health Care System, 795 Willow Rd., Menlo Park, CA 94025 USA; Center for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Rd., Menlo Park, CA 94025 USA.
Tyrone ThomasDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market St, Philadelphia, PA 19104 USA.
A C Del ReCenter for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Rd., Menlo Park, CA 94025 USA.
Kimberly BabsonNational Center for PTSD-Dissemination & Training Division, VA Palo Alto Health Care System, 795 Willow Rd., Menlo Park, CA 94025 USA.
James R McKayDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market St, Philadelphia, PA 19104 USA; Center of Excellence in Substance Abuse Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104 USA.

Funding

Effectiveness of Extended Treatments for Drug DependenceR01DA020623 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R. · 2006 to 2010
$3.6M
Adaptive Treatment Models for the Management of Drug Use DisordersK24DA029062 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R. · 2010 to 2021
$1.6M
NIDA NIH HHS K24 DA029062NIDA NIH HHS R01 DA020623
6 · The paper itself

Abstract

We tested the predictive validity of the Progress Assessment (PA), a brief counselor administered tool for use in measurement-based care for substance use disorders. The PA includes 5 items assessing relapse risk and 5 items assessing factors protective against relapse. Data were drawn from a completed study of continuing care for cocaine dependence (McKay et al., 2013) and includes 12 months of follow-up on158 participants (76% male) who received brief telephone or face-to-face sessions. Each session began with the administration of the PA, followed by cognitive-behavioral counseling tied to the results of the PA and anticipated risky situations. Outcome was assessed via urine toxicology every 3 months. As administered in an effectiveness trial, average PA risk and protective scales within each 3-month segment of the study predicted urine toxicology results at the end of that period, with higher risk scores and lower protective scores predicting greater rates of cocaine positive urine drug screens. PA scores did not predict dropout from continuing care participation. The 10-item PA shows promise as a pragmatic clinical tool for ongoing monitoring during continuing care for substance dependence.

Indexed as

AdultCounselingCounselorsFemaleFollow-Up StudiesHumansInterviews as TopicMaleMiddle AgedPredictive Value of TestsRecurrenceReproducibility of ResultsResearch ReportSubstance-Related DisordersTreatment OutcomeCocaine dependenceContinuing careDistance counselingProgress monitoring

Identifiers

PMID32711168
PMCPMC9434595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.